Non-Radiographic Axial Spondyloarthritis Market Summary

• The Non-Radiographic Axial Spondyloarthritis Market Size in the US was ~USD 900 Million in 2023, and is expected to grow at a significant CAGR during the forecast period.
• The leading Non-Radiographic Axial Spondyloarthritis Companies such as Novartis Pharmaceuticals, Sunshine Guojian Pharmaceutical (Shanghai) Co. Ltd., AbbVie, Suzhou Suncadia Biopharmaceuticals Co. Ltd., UCB Biopharma SRL, Merck Sharp & Dohme LLC, Pfizer, and others.

Non-Radiographic Axial Spondyloarthritis Market & Epidemiology Forecast

• According to DelveInsight’s estimates, the Non-Radiographic Axial Spondyloarthritis Prevalent Cases were approximately 1,580,000 in the 7MM, and these cases are anticipated to increase during the forecast period [2023–2034].
• According to the findings, the Non-Radiographic Axial Spondyloarthritis Diagnosed Cases in 2022, were approximately 903,000 in the 7MM. A clear gender disparity is observed, with female prevalent population showing predominance.~25% of women are misdiagnosed at first.
• Among EU4 countries, France accounted for the least number of Non-Radiographic Axial Spondyloarthritis Diagnosed Prevalent Cases, which were approximately ~40,000 in 2023.
• TALTZ was initially approved by the US FDA in 2019 for AS, and in July 2020, the US FDA expanded the approval of TALTZ to include non-radiographic axial spondyloarthritis. In 2023, TALTZ accounted for approximately 11% of the market share for non-radiographic axial spondyloarthritis in the US.
• The treatment approach for non-radiographic axial spondyloarthritis and AS is generally similar, though more FDA-approved medications are available for AS. The US FDA has approved UCB’s CIMZIA, Eli Lilly’s TALTZ, Novartis’s COSENTYX, and AbbVie’s RINVOQ for treating non-radiographic axial spondyloarthritis.

Request for Unlocking the Sample Page of the "Non-Radiographic Axial Spondyloarthritis Treatment Market"

Key Factors Driving the Non-Radiographic Axial Spondyloarthritis Market Growth

• Increasing Disease Awareness and Early Diagnosis

Greater awareness among healthcare professionals and patients is leading to early identification of nr-axSpA, driving treatment demand.

• Growing Adoption of Advanced Diagnostic Tools

Wider use of MRI and biomarker-based approaches enables earlier detection of inflammation, supporting market expansion.

• Rising Prevalence and Higher Recognition of Disease Burden

Improved classification criteria and growing global incidence are contributing to an expanding patient pool.

• Advancements in Biologic and Targeted Therapies

Increased availability of TNF inhibitors, IL-17 inhibitors, and emerging targeted small molecules is boosting therapeutic uptake.

• Strong Clinical Pipeline

Several promising therapies in phase II and III stages indicate future growth potential and increased treatment options.

DelveInsight's “Non-Radiographic Axial Spondyloarthritis Treatment Market Insights, Epidemiology and Market Forecast – 2034” report delivers an in-depth understanding of Non-Radiographic Axial Spondyloarthritis , historical and forecasted epidemiology as well as the Non-Radiographic Axial Spondyloarthritis Market Trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Non-Radiographic Axial Spondyloarthritis Treatment Market Report provides real-world prescription pattern analysis, market share of individual therapies, and historical and forecasted 7MM Non-Radiographic Axial Spondyloarthritis Market Size from 2020 to 2034. The report also covers current Non-Radiographic Axial Spondyloarthritis Treatment practices/algorithms and unmet medical needs to curate the best opportunities and assess the market’s underlying potential.

Non-Radiographic Axial Spondyloarthritis Disease Understanding and Treatment Algorithm

Non-Radiographic Axial Spondyloarthritis  Overview, Country-Specific Treatment Guidelines and Diagnosis

Non-Radiographic Axial Spondyloarthritis, or non-radiographic axial spondyloarthritis, is a chronic inflammatory condition. It’s characterized by active inflammation of the spine and sacroiliac (SI) joints, which are the joints that connect the lower spine and pelvis. Non-Radiographic Axial Spondyloarthritis  is a subtype of axial spondyloarthritis (axSpA). The exact causes of axSpA and its subtypes, including non-radiographic axial spondyloarthritis, aren’t fully understood. Genetics, environmental factors, and overactive immune responses are all thought to be involved. Some people who develop axSpA have a genetic predisposition to the condition. The most common gene implicated is HLA-B27, but having the HLA-B27 gene doesn’t guarantee one’ll develop axSpA. 

A rheumatologist will diagnose non-radiographic axial spondyloarthritis based on symptoms and diagnostic imaging, as there are no definitive tests for this condition. X-rays are essential for assessing sacroiliac (SI) joints for damage. According to the modified New York criteria, non-radiographic axial spondyloarthritis is diagnosed when there is inflammatory lower back pain for over three months, limited lumbar motion in sagittal and frontal planes, and/or limited chest expansion, plus sacroiliitis meeting Grade 2 in both joints or Grade 3 or 4 in at least one joint.

The Non-Radiographic Axial Spondyloarthritis Treatment Market Report provides an overview of non-radiographic axial spondyloarthritis pathophysiology, diagnostic approaches, and detailed treatment algorithm along with a real-world scenario of a patient’s journey beginning from the first symptom, the time taken for diagnosis to the entire treatment process.

Further details related to country-based variations in diagnosis are provided in the report

Non-Radiographic Axial Spondyloarthritis Treatment

Nonsteroidal anti-inflammatory drugs (NSAIDs) are the first-line pharmacologic treatment, followed by tumor necrosis factor - TNF, interleukin-17 - IL-17, or Janus kinase - JAK inhibitors. JAK inhibitors are new to the treatment algorithm and were placed on the same level with TNF and 17 inhibitors according to their approval status, but reference is made to usual practice with priority use of TNF and IL-17 inhibitors after NSAID failure. Importantly, objective detection of inflammatory activity (either on MRI or by elevated CRP) is one of the conditions for the administration of TNF, IL-17 or JAK inhibitors if definite radiographic sacroiliitis is not evidence. The FDA approved drugs include CIMZIA, TALTZ, RINVOQ, and COSENTYX.

Non-Radiographic Axial Spondyloarthritis Epidemiology

The Non-Radiographic Axial Spondyloarthritis Epidemiology chapter in the report provides historical as well as forecasted in the 7MM covering the United States, EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan from 2024 to 2034. The Non-Radiographic Axial Spondyloarthritis Epidemiology is segmented with detailed insights into total Non-Radiographic Axial Spondyloarthritis prevalent cases, total Non-Radiographic Axial Spondyloarthritis diagnosed prevalent cases, Non-Radiographic Axial Spondyloarthritis gender-specific diagnosed prevalent cases, and Non-Radiographic Axial Spondyloarthritis Gene-specific diagnosed prevalent cases

Key Findings from the Non-Radiographic Axial Spondyloarthritis Epidemiological Analysis

• By 2034, non-radiographic axial spondyloarthritis is expected to account for ~35% of prevalent cases of spondyloarthritis.
• Among non-radiographic axial spondyloarthritis patients, males represented ~43% of the diagnosed cases.
• In 2020, HLA-B27 positive cases accounted for ~80% of non-radiographic axial spondyloarthritis cases, while ~110,000 cases involved other genes.

Non-Radiographic Axial Spondyloarthritis Drug Analysis

The drug chapter segment of the Non-Radiographic Axial Spondyloarthritis Treatment Market Report encloses a detailed analysis of Non-Radiographic Axial Spondyloarthritis marketed drugs and late-stage (Phase III and Phase II) Non-Radiographic Axial Spondyloarthritis Pipeline Drugs. It also deep dives into the nonradiographic axial spondyloarthritis pivotal clinical trial details, recent and expected market approvals, patent details, the latest news, and recent deals and collaborations. 

Non-Radiographic Axial Spondyloarthritis Marketed Drugs

• RINVOQ:  AbbVie 

RINVOQ is a JAK inhibitor that is being studied in several immune-mediated inflammatory diseases. In human leukocyte cellular assays, RINVOQ inhibited cytokine-induced STAT phosphorylation mediated by JAK1 and JAK1/JAK3 more potently than JAK2/JAK2 mediated STAT phosphorylation. The relevance of inhibition of specific JAK enzymes to therapeutic effectiveness and safety is not currently known. 

In October 2022, the US FDA approved RINVOQ for the treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation who have had an inadequate response or intolerance to tumor necrosis factor (TNF) blocker therapy. The FDA approval decision is supported by data from the Phase III SELECT-AXIS 2 clinical trial, which assessed the efficacy, safety, and tolerability of RINVOQ in adults with active non-radiographic axial spondyloarthritis. It is approved in Europe and Japan as well for the Non-Radiographic Axial Spondyloarthritis Treatment.

• CIMZIA (certolizumab pegol): UCB

CIMZIA is the only Fc-free, PEGylated anti-TNF (tumor necrosis factor). CIMZIA binds to human TNFα with a KD of 90pM. TNFα is a key pro-inflammatory cytokine with a central role in inflammatory processes. Certolizumab pegol selectively neutralizes TNFα (IC90 of 4 ng/mL for inhibition of human TNFα in the in vitro L929 murine fibrosarcoma cytotoxicity assay) but does not neutralize lymphotoxin α (TNFβ).

In March 2019, the US FDA has approved extended label for CIMZIA (certolizumab pegol) to include a new indication for the treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation. The FDA approval was based on the C-AXSPAND Phase III study in adults with non-radiographic axial spondyloarthritis.

Non-Radiographic Axial Spondyloarthritis  Market Outlook

Growing awareness about non-radiographic axial spondyloarthritis among healthcare professionals and patients has expanded the patient pool. This contributes to market growth. Biologic therapies, such as tumor necrosis factor (TNF) inhibitors and interleukin inhibitors, have shown efficacy in managing non-radiographic axial spondyloarthritis symptoms. Research and development efforts continue to improve treatment options, leading to better outcomes for patients. In June 2023, the European Commission approved BIMZELX for the treatment of active axSpA. It is the first and only IL-17A and IL-17F inhibitor approved in the European Union for this condition. By 2034, BIMZELX is expected to capture approximately 3% of the market share for non-radiographic axial spondyloarthritis. In 2023, the Conventional Therapies held the largest market share for non-radiographic axial spondyloarthritis in Japan, valued at USD 1.74 million.

Latest KOL-Views on Non-Radiographic Axial Spondyloarthritis

To keep up with the real-world scenario in current and emerging market trends, we take opinions from Key Industry leaders working in the domain through primary research to fill the data gaps and validate our secondary research. Industry Experts were contacted for insights on the evolving treatment landscape, patient reliance on conventional therapies, patient therapy switching acceptability, and drug uptake along with challenges related to accessibility.

DelveInsight’s analysts connected with 10+ KOLs to gather insights; however, interviews were conducted with 5+ KOLs in the 7MM. Their opinion helps understand and validate current and emerging treatment patterns of Non-Radiographic Axial Spondyloarthritis. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.

Non-Radiographic Axial Spondyloarthritis Qualitative Analysis

We perform Qualitative and market Intelligence analysis using various approaches, such as SWOT analysis and Conjoint Analysis. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of gaps in disease diagnosis, patient awareness, physician acceptability, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided. Conjoint Analysis analyzes therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.

In efficacy, the trial’s primary and secondary outcome measures are evaluated; for instance, in event-free survival, one of the most important primary outcome measures is event-free survival and overall survival. Further, the therapies’ safety is evaluated wherein the acceptability, tolerability, and adverse events are majorly observed, and it sets a clear understanding of the side effects posed by the drug in the trials. In addition, the scoring is also based on the probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of therapies are decided. 

Non-Radiographic Axial Spondyloarthritis Market Access and Reimbursement

The Non-Radiographic Axial Spondyloarthritis Therapeutics Market Report provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of currently used therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.

Non-Radiographic Axial Spondyloarthritis Market Report Scope

• The Non-Radiographic Axial Spondyloarthritis Market Report covers a segment of key events, an executive summary descriptive overview, explaining its causes, signs and symptoms, pathogenesis, and currently available therapies.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, and disease progression along with country specific treatment guidelines.
• Additionally, an all-inclusive account of both the current and emerging therapies, along with the elaborative profiles of late-stage and prominent therapies, will have an impact on the current treatment landscape.
• A detailed review of the Non-Radiographic Axial Spondyloarthritis Treatment Market, historical and forecasted Non-Radiographic Axial Spondyloarthritis Market Size, Non-Radiographic Axial Spondyloarthritis Drugs Market Share by therapies, detailed assumptions, and rationale behind our approach is included in the report, covering the 7MM drug outreach.
• The Non-Radiographic Axial Spondyloarthritis Treatment Market Report provides an edge while developing business strategies, by understanding trends, through SWOT analysis and expert insights/KOL views, patient journey, and treatment preferences that help in shaping and driving the 7MM Non-Radiographic Axial Spondyloarthritis Drugs Market.

Non-Radiographic Axial Spondyloarthritis Market Report Insights

• Patient-based Non-Radiographic Axial Spondyloarthritis Market Forecasting
• Therapeutic Approaches
• Non-Radiographic Axial Spondyloarthritis Pipeline Analysis
• Non-Radiographic Axial Spondyloarthritis Market Size and Trends
• Existing and future Non-Radiographic Axial Spondyloarthritis Drugs Market Opportunity 

Non-Radiographic Axial Spondyloarthritis Market Report Key Strengths

• 11 Years Non-Radiographic Axial Spondyloarthritis Market Forecast
• 7MM Coverage 
• Non-Radiographic Axial Spondyloarthritis Epidemiology Segmentation
• Inclusion of Country specific treatment guidelines
• KOL’s feedback on approved and emerging therapies 
• Key Cross Competition 
• Conjoint analysis
• Non-Radiographic Axial Spondyloarthritis Drugs Uptake
• Key Non-Radiographic Axial Spondyloarthritis Market Forecast Assumptions

Non-Radiographic Axial Spondyloarthritis Market Report Assessment

• Current Non-Radiographic Axial Spondyloarthritis Treatment Practices
• Non-Radiographic Axial Spondyloarthritis Unmet Needs
• Non-Radiographic Axial Spondyloarthritis Pipeline Drugs Profiles
• Non-Radiographic Axial Spondyloarthritis Drugs Market Attractiveness
• Qualitative Analysis (SWOT and Conjoint Analysis)

Key Questions Answered in the Non-Radiographic Axial Spondyloarthritis Market Report

• What is the growth rate of the 7MM Non-Radiographic Axial Spondyloarthritis treatment market?
• What was the Non-Radiographic Axial Spondyloarthritis Market Size, the market size by therapies, Non-Radiographic Axial Spondyloarthritis Drugs Market Share (%) distribution in 2020, and what would it look like in 2034? What are the contributing factors/key catalysts for this growth?
• Is there any unexplored patient setting that can open the window for growth in the future?
• What are the pricing variations among different geographies for approved and off-label therapies?
• How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends? Although multiple expert guidelines recommend testing for targetable mutations before therapy initiation, why do barriers to testing remain high?
• What are the current and emerging options for the treatment of Non-Radiographic Axial Spondyloarthritis? 
• How many companies are developing therapies for the treatment of Non-Radiographic Axial Spondyloarthritis?
• What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitations of existing therapies? 
• Patient acceptability in terms of preferred treatment options as per real-world scenarios?
• What are the country-specific accessibility issues of expensive, recently approved therapies? 

Reasons to Buy the Non-Radiographic Axial Spondyloarthritis Market Report

• The Non-Radiographic Axial Spondyloarthritis Drugs Market Report will help in developing business strategies by understanding the latest trends and changing treatment dynamics driving the Non-Radiographic Axial Spondyloarthritis Market.
• Insights on patient burden/disease Non-Radiographic Axial Spondyloarthritis Prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years
• Understand the existing market opportunities in varying geographies and the growth potential over the coming years.
• Distribution of historical and current patient share based on real-world prescription data along with reported sales of approved products in the US, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
• Identifying strong upcoming players in the Non-Radiographic Axial Spondyloarthritis Drugs Market will help devise strategies to help get ahead of competitors.
• Detailed analysis and ranking of class-wise potential current and emerging therapies under the conjoint analysis section to provide visibility around leading classes.
• Highlights of access and reimbursement policies of approved therapies, barriers to accessibility of expensive off-label therapies, and patient assistance programs.
• To understand Key Opinion Leaders’ perspectives around the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights on the unmet needs of the existing Non-Radiographic Axial Spondyloarthritis Drugs Market so that the upcoming players can strengthen their development and launch strategy.

Stay updated with us for Recent Articles @ New DelveInsight Blogs